Review



raw intensity files from microarray experiment  (Partek)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Partek raw intensity files from microarray experiment
    Genetic deletion of SphK1 reduced CLDN2 in HER2/neu-induced mice breast tumors. (A) Whole genome expression profile evaluated by <t>microarray</t> analysis assessed the expression of 39000 gene transcripts. Gene expression microarray heatmap (n = 2 per group) of dysregulated genes. (B) Twenty molecules with the most significant expression changes (10 up-regulation and 20 down-regulation) between SphK1+/+ and SphK1−/− tumors are shown. (C) CLDN2 mRNA expression in tumors from SphK1+/+ and SphK1−/− mice was confirmed by qRT-PCR analysis and analyzed by unpaired t-test. ****P ≤ 0.0001 vs. SphK1+/+. (D) Representative paraffin-tumor sections immunostained for CLDN2 in tumors from SphK1+/+ and SphK1−/− mice (P = 0.1339).
    Raw Intensity Files From Microarray Experiment, supplied by Partek, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/raw intensity files from microarray experiment/product/Partek
    Average 90 stars, based on 1 article reviews
    raw intensity files from microarray experiment - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model"

    Article Title: Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model

    Journal: Carcinogenesis

    doi: 10.1093/carcin/bgx097

    Genetic deletion of SphK1 reduced CLDN2 in HER2/neu-induced mice breast tumors. (A) Whole genome expression profile evaluated by microarray analysis assessed the expression of 39000 gene transcripts. Gene expression microarray heatmap (n = 2 per group) of dysregulated genes. (B) Twenty molecules with the most significant expression changes (10 up-regulation and 20 down-regulation) between SphK1+/+ and SphK1−/− tumors are shown. (C) CLDN2 mRNA expression in tumors from SphK1+/+ and SphK1−/− mice was confirmed by qRT-PCR analysis and analyzed by unpaired t-test. ****P ≤ 0.0001 vs. SphK1+/+. (D) Representative paraffin-tumor sections immunostained for CLDN2 in tumors from SphK1+/+ and SphK1−/− mice (P = 0.1339).
    Figure Legend Snippet: Genetic deletion of SphK1 reduced CLDN2 in HER2/neu-induced mice breast tumors. (A) Whole genome expression profile evaluated by microarray analysis assessed the expression of 39000 gene transcripts. Gene expression microarray heatmap (n = 2 per group) of dysregulated genes. (B) Twenty molecules with the most significant expression changes (10 up-regulation and 20 down-regulation) between SphK1+/+ and SphK1−/− tumors are shown. (C) CLDN2 mRNA expression in tumors from SphK1+/+ and SphK1−/− mice was confirmed by qRT-PCR analysis and analyzed by unpaired t-test. ****P ≤ 0.0001 vs. SphK1+/+. (D) Representative paraffin-tumor sections immunostained for CLDN2 in tumors from SphK1+/+ and SphK1−/− mice (P = 0.1339).

    Techniques Used: Expressing, Microarray, Gene Expression, Quantitative RT-PCR

    SphK1 and CLDN2 levels are increased in HER2-positive breast cancers in humans. Tissue microarray containing breast cancer samples from 92 HER2-positive breast cancer patients and matched adjacent normal breast tissues (n = 34) are stained for SphK1 and CLDN2. Staining were scored based on the intensity (0–3) and proportion (0–3), and the total scores were used for the analysis. [(A) and (B)] SphK1 and CLDN2 expressions were compared with pathological features including grade, stage and hormone receptor status. [(C) and (D)] Representative image of high, moderate and low SphK1 and CLDN2 expressing tumors.
    Figure Legend Snippet: SphK1 and CLDN2 levels are increased in HER2-positive breast cancers in humans. Tissue microarray containing breast cancer samples from 92 HER2-positive breast cancer patients and matched adjacent normal breast tissues (n = 34) are stained for SphK1 and CLDN2. Staining were scored based on the intensity (0–3) and proportion (0–3), and the total scores were used for the analysis. [(A) and (B)] SphK1 and CLDN2 expressions were compared with pathological features including grade, stage and hormone receptor status. [(C) and (D)] Representative image of high, moderate and low SphK1 and CLDN2 expressing tumors.

    Techniques Used: Microarray, Staining, Expressing



    Similar Products

    raw intensity files from microarray experiment  (Partek)
    90
    Partek raw intensity files from microarray experiment
    Genetic deletion of SphK1 reduced CLDN2 in HER2/neu-induced mice breast tumors. (A) Whole genome expression profile evaluated by <t>microarray</t> analysis assessed the expression of 39000 gene transcripts. Gene expression microarray heatmap (n = 2 per group) of dysregulated genes. (B) Twenty molecules with the most significant expression changes (10 up-regulation and 20 down-regulation) between SphK1+/+ and SphK1−/− tumors are shown. (C) CLDN2 mRNA expression in tumors from SphK1+/+ and SphK1−/− mice was confirmed by qRT-PCR analysis and analyzed by unpaired t-test. ****P ≤ 0.0001 vs. SphK1+/+. (D) Representative paraffin-tumor sections immunostained for CLDN2 in tumors from SphK1+/+ and SphK1−/− mice (P = 0.1339).
    Raw Intensity Files From Microarray Experiment, supplied by Partek, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/raw intensity files from microarray experiment/product/Partek
    Average 90 stars, based on 1 article reviews
    raw intensity files from microarray experiment - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Genetic deletion of SphK1 reduced CLDN2 in HER2/neu-induced mice breast tumors. (A) Whole genome expression profile evaluated by microarray analysis assessed the expression of 39000 gene transcripts. Gene expression microarray heatmap (n = 2 per group) of dysregulated genes. (B) Twenty molecules with the most significant expression changes (10 up-regulation and 20 down-regulation) between SphK1+/+ and SphK1−/− tumors are shown. (C) CLDN2 mRNA expression in tumors from SphK1+/+ and SphK1−/− mice was confirmed by qRT-PCR analysis and analyzed by unpaired t-test. ****P ≤ 0.0001 vs. SphK1+/+. (D) Representative paraffin-tumor sections immunostained for CLDN2 in tumors from SphK1+/+ and SphK1−/− mice (P = 0.1339).

    Journal: Carcinogenesis

    Article Title: Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model

    doi: 10.1093/carcin/bgx097

    Figure Lengend Snippet: Genetic deletion of SphK1 reduced CLDN2 in HER2/neu-induced mice breast tumors. (A) Whole genome expression profile evaluated by microarray analysis assessed the expression of 39000 gene transcripts. Gene expression microarray heatmap (n = 2 per group) of dysregulated genes. (B) Twenty molecules with the most significant expression changes (10 up-regulation and 20 down-regulation) between SphK1+/+ and SphK1−/− tumors are shown. (C) CLDN2 mRNA expression in tumors from SphK1+/+ and SphK1−/− mice was confirmed by qRT-PCR analysis and analyzed by unpaired t-test. ****P ≤ 0.0001 vs. SphK1+/+. (D) Representative paraffin-tumor sections immunostained for CLDN2 in tumors from SphK1+/+ and SphK1−/− mice (P = 0.1339).

    Article Snippet: Partek pre-processes raw intensity files from microarray experiment using GCRMA’s background subtraction and uses quantile normalization as the normalization technique.

    Techniques: Expressing, Microarray, Gene Expression, Quantitative RT-PCR

    SphK1 and CLDN2 levels are increased in HER2-positive breast cancers in humans. Tissue microarray containing breast cancer samples from 92 HER2-positive breast cancer patients and matched adjacent normal breast tissues (n = 34) are stained for SphK1 and CLDN2. Staining were scored based on the intensity (0–3) and proportion (0–3), and the total scores were used for the analysis. [(A) and (B)] SphK1 and CLDN2 expressions were compared with pathological features including grade, stage and hormone receptor status. [(C) and (D)] Representative image of high, moderate and low SphK1 and CLDN2 expressing tumors.

    Journal: Carcinogenesis

    Article Title: Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model

    doi: 10.1093/carcin/bgx097

    Figure Lengend Snippet: SphK1 and CLDN2 levels are increased in HER2-positive breast cancers in humans. Tissue microarray containing breast cancer samples from 92 HER2-positive breast cancer patients and matched adjacent normal breast tissues (n = 34) are stained for SphK1 and CLDN2. Staining were scored based on the intensity (0–3) and proportion (0–3), and the total scores were used for the analysis. [(A) and (B)] SphK1 and CLDN2 expressions were compared with pathological features including grade, stage and hormone receptor status. [(C) and (D)] Representative image of high, moderate and low SphK1 and CLDN2 expressing tumors.

    Article Snippet: Partek pre-processes raw intensity files from microarray experiment using GCRMA’s background subtraction and uses quantile normalization as the normalization technique.

    Techniques: Microarray, Staining, Expressing